16 citations,
July 2020 in “International Journal of Molecular Sciences” Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
223 citations,
September 2018 in “Rheumatology” JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
3 citations,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
1 citations,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
September 2014 in “SciBX” JAK inhibitors may help treat alopecia areata and promote hair regrowth.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
53 citations,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
26 citations,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
16 citations,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
1 citations,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
1 citations,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” The summit aimed to speed up finding treatments for alopecia areata.
63 citations,
April 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
1 citations,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
37 citations,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
3 citations,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
2 citations,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
14 citations,
February 2021 in “Journal of the European Academy of Dermatology and Venereology” A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
8 citations,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
1 citations,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
January 2016 in “Springer eBooks” Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.